vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

ESCALADE INC is the larger business by last-quarter revenue ($62.6M vs $57.6M, roughly 1.1× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -2.2%). ESCALADE INC produced more free cash flow last quarter ($13.7M vs $-167.0M).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

ESCA vs PHAT — Head-to-Head

Bigger by revenue
ESCA
ESCA
1.1× larger
ESCA
$62.6M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+96.3% gap
PHAT
94.1%
-2.2%
ESCA
More free cash flow
ESCA
ESCA
$180.7M more FCF
ESCA
$13.7M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESCA
ESCA
PHAT
PHAT
Revenue
$62.6M
$57.6M
Net Profit
$3.7M
Gross Margin
27.7%
86.7%
Operating Margin
8.2%
Net Margin
5.9%
Revenue YoY
-2.2%
94.1%
Net Profit YoY
37.1%
71.6%
EPS (diluted)
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
PHAT
PHAT
Q4 25
$62.6M
$57.6M
Q3 25
$67.8M
$49.5M
Q2 25
$54.3M
$39.5M
Q1 25
$55.5M
$28.5M
Q4 24
$63.9M
$29.7M
Q3 24
$67.7M
$16.4M
Q2 24
$62.5M
$7.3M
Q1 24
$57.3M
Net Profit
ESCA
ESCA
PHAT
PHAT
Q4 25
$3.7M
Q3 25
$5.6M
$-30.0M
Q2 25
$1.8M
$-75.8M
Q1 25
$2.6M
$-94.3M
Q4 24
$2.7M
Q3 24
$5.7M
$-85.6M
Q2 24
$2.8M
$-91.4M
Q1 24
$1.8M
Gross Margin
ESCA
ESCA
PHAT
PHAT
Q4 25
27.7%
86.7%
Q3 25
28.1%
87.5%
Q2 25
24.7%
87.2%
Q1 25
26.7%
86.9%
Q4 24
24.9%
87.1%
Q3 24
24.8%
85.6%
Q2 24
24.2%
81.2%
Q1 24
25.0%
Operating Margin
ESCA
ESCA
PHAT
PHAT
Q4 25
8.2%
Q3 25
10.8%
-30.8%
Q2 25
4.8%
-151.7%
Q1 25
6.6%
-276.5%
Q4 24
7.1%
Q3 24
11.8%
-433.0%
Q2 24
7.1%
-1055.4%
Q1 24
5.3%
Net Margin
ESCA
ESCA
PHAT
PHAT
Q4 25
5.9%
Q3 25
8.2%
-60.5%
Q2 25
3.4%
-191.9%
Q1 25
4.7%
-330.7%
Q4 24
4.2%
Q3 24
8.4%
-523.3%
Q2 24
4.5%
-1248.6%
Q1 24
3.1%
EPS (diluted)
ESCA
ESCA
PHAT
PHAT
Q4 25
$0.27
Q3 25
$0.40
$-0.41
Q2 25
$0.13
$-1.05
Q1 25
$0.19
$-1.31
Q4 24
$0.20
Q3 24
$0.40
$-1.32
Q2 24
$0.20
$-1.56
Q1 24
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$130.0M
Total DebtLower is stronger
$18.5M
$209.1M
Stockholders' EquityBook value
$173.2M
$-438.2M
Total Assets
$222.1M
$259.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
PHAT
PHAT
Q4 25
$130.0M
Q3 25
$135.2M
Q2 25
$149.6M
Q1 25
$212.3M
Q4 24
$297.3M
Q3 24
$334.7M
Q2 24
$276.2M
Q1 24
Total Debt
ESCA
ESCA
PHAT
PHAT
Q4 25
$18.5M
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$25.6M
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
ESCA
ESCA
PHAT
PHAT
Q4 25
$173.2M
$-438.2M
Q3 25
$172.3M
$-422.5M
Q2 25
$168.3M
$-405.8M
Q1 25
$168.8M
$-338.4M
Q4 24
$169.0M
$-253.6M
Q3 24
$170.1M
$-187.1M
Q2 24
$166.0M
$-233.8M
Q1 24
$164.7M
Total Assets
ESCA
ESCA
PHAT
PHAT
Q4 25
$222.1M
$259.1M
Q3 25
$232.5M
$240.3M
Q2 25
$218.3M
$250.2M
Q1 25
$222.1M
$294.2M
Q4 24
$226.3M
$378.3M
Q3 24
$244.9M
$387.0M
Q2 24
$243.1M
$319.4M
Q1 24
$256.3M
Debt / Equity
ESCA
ESCA
PHAT
PHAT
Q4 25
0.11×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
PHAT
PHAT
Operating Cash FlowLast quarter
$14.9M
$-166.8M
Free Cash FlowOCF − Capex
$13.7M
$-167.0M
FCF MarginFCF / Revenue
21.8%
-290.0%
Capex IntensityCapex / Revenue
2.0%
0.4%
Cash ConversionOCF / Net Profit
4.02×
TTM Free Cash FlowTrailing 4 quarters
$28.5M
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
PHAT
PHAT
Q4 25
$14.9M
$-166.8M
Q3 25
$-965.0K
$-14.1M
Q2 25
$13.3M
$-62.7M
Q1 25
$3.8M
$-84.9M
Q4 24
$12.3M
$-266.8M
Q3 24
$10.5M
$-63.6M
Q2 24
$13.3M
$-70.7M
Q1 24
$7.0K
Free Cash Flow
ESCA
ESCA
PHAT
PHAT
Q4 25
$13.7M
$-167.0M
Q3 25
$-1.3M
$-14.1M
Q2 25
$12.9M
$-62.8M
Q1 25
$3.2M
$-84.9M
Q4 24
$11.7M
$-266.9M
Q3 24
$10.2M
$-63.6M
Q2 24
$12.5M
$-70.8M
Q1 24
$-350.0K
FCF Margin
ESCA
ESCA
PHAT
PHAT
Q4 25
21.8%
-290.0%
Q3 25
-1.9%
-28.6%
Q2 25
23.7%
-159.0%
Q1 25
5.9%
-297.9%
Q4 24
18.4%
-899.8%
Q3 24
15.0%
-389.0%
Q2 24
20.0%
-966.2%
Q1 24
-0.6%
Capex Intensity
ESCA
ESCA
PHAT
PHAT
Q4 25
2.0%
0.4%
Q3 25
0.4%
0.1%
Q2 25
0.8%
0.2%
Q1 25
1.0%
0.1%
Q4 24
0.9%
0.5%
Q3 24
0.5%
0.3%
Q2 24
1.3%
0.6%
Q1 24
0.6%
Cash Conversion
ESCA
ESCA
PHAT
PHAT
Q4 25
4.02×
Q3 25
-0.17×
Q2 25
7.28×
Q1 25
1.45×
Q4 24
4.55×
Q3 24
1.85×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons